
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific has demonstrated a robust performance with significant year-over-year sales growth across multiple product categories, including a 35% increase in Watchman sales and a remarkable 63% growth in electrophysiology (EP), indicating strong market demand and share gains. The company has provided favorable guidance for Q4, projecting organic sales growth between 11-13% and an adjusted EPS range of $0.48 to $0.52, reflecting positive trends in its coronary therapies and diagnostics franchises. Additionally, the promising outlook for the Nalu product, with anticipated sales exceeding $60 million in 2025 and a growth rate of over 25% in 2026, further supports a positive long-term financial outlook for Boston Scientific.
Bears say
Boston Scientific faces a negative outlook due to expected foreign exchange headwinds, anticipated to reduce adjusted earnings by approximately $0.04 for the full year. The company's reliance on mature markets for its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios exposes it to ongoing pricing pressures, thereby limiting revenue growth potential. Additionally, challenges in product development and integration of new acquisitions could further hinder Boston Scientific's ability to meet internal revenue expectations, negatively impacting overall business performance.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares